Last edition
News about "tumor cells "
Merck is set to showcase new data at ESMO 2025, highlighting advancements in oncology across emerging tumor types and early-stage diseases, with positive survival results from KEYNOTE-905 and KEYNOTE-B96 trials demonstrating the impact of KEYTRUDA (pembrolizumab) in bladder and ovarian cancers.
Tumor Cells | 11/10/2025 | By Dineshwori | 900
ABL Bio Signs Clinical Alliance with MSD to Evaluate ABL103 with KEYTRUDA
Under the terms of the agreement, ABL Bio will conduct a phase 1b/2 clinical trial to evaluate the safety and efficacy of ABL103 in combination with KEYTRUDA. In this combination study, MSD will supply KEYTRUDA.
Tumor Cells | 07/10/2024 | By Aishwarya | 641
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy